Opinion

Aaron Goodman: My prediction (American Society of Hematology 2023)

Photo from Aaron Goodman/X

Dec 9, 2023, 16:37

Aaron Goodman: My prediction (American Society of Hematology 2023)

Aaron Goodman shared a post on X/Twitter:

“My prediction is the plenary session at American Society of Hematology in 2033 will be 10 drugs vs 9 drugs in myeloma end point Minimal Residual Disease (MRD). IKRd vs KRd in newly diagnosed multiple myeloma.

For details, click here.
Source: Aaron Goodman/X

Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.

Aaron Goodman American Society of Hematology cancer Minimal Residual Disease (MRD) multiple myeloma National Comprehensive Cancer Network OncoDaily Oncology University of California

Shannon Miller and Ovarian Cancer: How She Went Against, How She Survived, and More

ASTRO Overview: Everything You Need to Know About the Leading Radiation Oncology Society

Kamala Harris vs Donald Trump on Cancer: From Cancer Moonshot to Right to Act, Funding, Research and Future

Dr. Richard Pazdur: 25 Years of Transforming Oncology Drug Development at the FDA

New €4.9m Beaumont RCSI Cancer Centre and Irish Cancer Society Partnership to Transform Lung Cancer Care in Ireland

Special Coverage